Litcius/Paper detail

AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial

Florian Heitz, Christian Marth, Stéphanie Henry, Alexander Reuß, David Cibula, Lydia Gaba Garcia, Nicoletta Colombo, Barbara Schmalfeld, Nikolaus de Gregorio, Pauline Wimberger, Annette Hasenburg, Jalid Sehouli, Martina Gropp‐Meier, Philip C. Schouten, Eric Hahnen, Jan Hauke, Sandra Polleis, Philipp Harter

2023International Journal of Gynecological Cancer18 citationsDOIOpen Access PDF

Topics & Concepts

MedicineTaxaneBevacizumabCarboplatinOncologyChemotherapyOvarian cancerInternal medicineCancerBreast cancerCisplatinPARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentAdvanced Breast Cancer Therapies
AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial | Litcius